Eribulin-induced liver dysfunction as a prognostic indicator of survival of metastatic breast cancer patients: a retrospective study

BACKGROUND: Eribulin is a non-taxane, microtubule dynamics inhibitor that increases survival of patients with metastatic breast cancer. Although eribulin is well tolerated in patients with heavily pretreated disease, eribulin-induced liver dysfunction (EILD) can occur, resulting in treatment modific...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:BMC Cancer
Autores principales: Kobayashi, Takayuki, Tomomatsu, Jyunichi, Fukada, Ippei, Shibayama, Tomoko, Teruya, Natsuki, Ito, Yoshinori, Iwase, Takuji, Ohno, Shinji, Takahashi, Shunji
Formato: Artigo
Lenguaje:Inglês
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC4936231/
https://ncbi.nlm.nih.gov/pubmed/27389013
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2436-5
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares